Cargando…

Identification of FOXM1 as a specific marker for triple-negative breast cancer

The present study aimed to identify the therapeutic role of the forkhead box M1 (FOXM1)-associated pathway in triple-negative breast cancer (TNBC). Using a Cancer Landscapes-based analysis, a gene regulatory network model was constructed. The present results demonstrated that FOXM1 occupies a key po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Yanli, Wang, Qixue, Xie, Yingbin, Qiao, Xiaoxia, Zhang, Shun, Wang, Yanan, Yang, Yongbin, Zhang, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254995/ https://www.ncbi.nlm.nih.gov/pubmed/30365046 http://dx.doi.org/10.3892/ijo.2018.4598

Ejemplares similares

Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
por: Yang, Na, et al.
Publicado: (2019)

The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer
por: Ulhaka, Karan, et al.
Publicado: (2021)

Suppression of Tumor Growth, Metastasis, and Signaling Pathways by Reducing FOXM1 Activity in Triple Negative Breast Cancer
por: Dey, Parama, et al.
Publicado: (2020)

circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression
por: Chen, Bo, et al.
Publicado: (2018)

Integrated network analysis identifies hsa-miR-4756-3p as a regulator of FOXM1 in Triple Negative Breast Cancer
por: Gu, Yuanliang, et al.
Publicado: (2019)

CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2018)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
por: Li, Yu, et al.
Publicado: (2021)

Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells
por: Liu, Tingting, et al.
Publicado: (2021)

Author Correction: Integrated network analysis identifies hsa-miR-4756-3p as a regulator of FOXM1 in Triple Negative Breast Cancer
por: Gu, Yuanliang, et al.
Publicado: (2021)

FOXM1: Functional Roles of FOXM1 in Non-Malignant Diseases
por: Zhang, Zhenwang, et al.
Publicado: (2023)

Genomic landscapes by multiregion sequencing combined with circulation tumor DNA detection contribute to molecular diagnosis in glioblastomas
por: Yang, Chao, et al.
Publicado: (2019)

Kinesin family member 23, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/β-catenin pathway
por: Li, Zhi, et al.
Publicado: (2022)

The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3
por: Zhang, Zhenwang, et al.
Publicado: (2019)

The multifaceted roles of FOXM1 in pulmonary disease
por: Li, Yumei, et al.
Publicado: (2019)

Aberrantly high activation of a FoxM1–STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers
por: Liu, Jun, et al.
Publicado: (2021)

Simvastatin induced ferroptosis for triple-negative breast cancer therapy
por: Yao, Xianxian, et al.
Publicado: (2021)

A novel FOXM1 isoform, FOXM1D, promotes epithelial–mesenchymal transition and metastasis through ROCKs activation in colorectal cancer
por: Zhang, X, et al.
Publicado: (2017)

Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1
por: Yu, Jiao, et al.
Publicado: (2017)

Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer
por: Chen, Bo, et al.
Publicado: (2018)

Multiplexed immunofluorescence analysis of CAF-markers, EZH2 and FOXM1 in gastric tissue: associations with clinicopathological parameters and clinical outcomes
por: Sun, Hui, et al.
Publicado: (2022)

TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma
por: Yang, Shixue, et al.
Publicado: (2022)

Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis
por: Xie, Yingbin, et al.
Publicado: (2019)

Fascin‐1 as a novel diagnostic marker of triple‐negative breast cancer
por: Wang, Chao‐Qun, et al.
Publicado: (2016)

FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells
por: Hamurcu, Zuhal, et al.
Publicado: (2016)

FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10
por: Xie, Tao, et al.
Publicado: (2016)

The roles of FOXM1 in pancreatic stem cells and carcinogenesis
por: Quan, Ming, et al.
Publicado: (2013)

Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms
por: Yeh, Shan-Ju, et al.
Publicado: (2021)

Cancer cell line specific co-factors modulate the FOXM1 cistrome
por: Wang, Yue, et al.
Publicado: (2017)

The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer
por: Zhu, Xiaoxia, et al.
Publicado: (2015)

Expression and functional characterization of FOXM1 in non-small cell lung cancer
por: Zhang, Yan, et al.
Publicado: (2018)

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer
por: Chen, Xuanzhao, et al.
Publicado: (2023)

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
por: Anurag, Meenakshi, et al.
Publicado: (2022)

Identification of a novel glycolysis-related prognosis risk signature in triple-negative breast cancer
por: Ruan, Yuxia, et al.
Publicado: (2023)

Identification of potential oncogenes in triple-negative breast cancer based on bioinformatics analyses
por: Xiao, Xiao, et al.
Publicado: (2021)

Impact of histotypes on preferential organ‐specific metastasis in triple‐negative breast cancer
por: Li, Yaming, et al.
Publicado: (2019)

FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair
por: Wang, Shu-Ping, et al.
Publicado: (2021)

Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways
por: Maharjan, Sushma, et al.
Publicado: (2023)

Identification of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer
por: Chung, Jee Min, et al.
Publicado: (2018)

Identification of novel long non-coding RNAs in triple-negative breast cancer
por: Shen, Xiaokun, et al.
Publicado: (2015)

CXCR2 is a novel cancer stem-like cell marker for triple-negative breast cancer
por: Wang, Yuyi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jv28asledpa2gj0asg3hn2ncsi